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Background: The bronchoprotective effect of caffeine on histamine challenge testing (HCT)
has been studied with equivocal results. Current guidelines for bronchoprovocation testing
recommend exclusion of caffeine the day of testing. The effects of caffeine on methacholine
challenge testing (MCT), now more commonly performed than histamine challenge, are
unknown.
Methods: Sixteen well-controlled asthmatics with a forced expiratory volume in 1 s
(FEV1) > 65% predicted and methacholine provocation concentration causing a 20% fall in
FEV1 (PC20)  16 mg/ml participated in a randomized single-blind crossover study. The two
treatments included 16 ounces of caffeinated and decaffeinated coffee given on two separate
days. The fraction of exhaled nitric oxide (eNO) and FEV1 were measured before and 1 h after
each treatment. One hour post treatment blood was drawn for serum caffeine level and the
MCT was done.
Results: Fourteen subjects completed the study; there were no adverse events. No significant
bronchodilation was seen between the mean FEV1 values before and after the caffeinated
treatment (3.31  0.75 L and 3.36  0.74 L, respectively). No significant bronchoprotection
was seen between the caffeinated and decaffeinated treatment’s geometric mean PC20 values
(1.35 mg/ml and 1.36 mg/ml, respectively). Mean eNO values before and after caffeinated
treatment were not significantly different (31.2  19.6 ppb and 31.5  20.4 ppb).
Conclusion: The amount of caffeine in a normal dietary serving of a 16oz cup of coffee is not
enough to cause significant bronchoprotection, bronchodilation, or decrease eNO values.
Registered at http://clinicaltrials.gov: NCT01057875.
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Coffee and methacholine responsiveness 1607Introduction FEV1  65% predicted, and no respiratory tract infection orCaffeine is found in many beverages and foods.1,2 It was
once believed that the consumption of caffeine was leading
to an underdiagnosis of asthma, but this has since been
disproved.3e5 The bronchodilating effects of a normal die-
tary intake of caffeine, two cups, is not clinically significant
but theophylline, which is chemically similar to caffeine,
results in significant bronchodilation when administered in
small doses and has been used in clinical research and as
a treatment for asthma.4e7 Although a normal dietary
intake of caffeine is ineffective in the treatment of asthma
it is still not consumed prior to diagnostic tests to help yield
accurate results.
Currently, newer techniques and tools are used in the
diagnosis of asthma, such as the methacholine challenge
test (MCT) and exhaled nitric oxide (eNO). Methacholine,
a muscarinic receptor agonist acts on airway smooth muscle
and causes bronchoconstriction in asthmatics.8e10 It is now
often used instead of histamine in bronchial provocation
testing to assess airway hyperresponsiveness (AHR) because
of fewer systemic side effects.8e10 The ATS has guidelines
in place for MCT to help with reproducibility to within one
to two doubling doses between provocation chal-
lenges.9,11,12 Subjects are required to refrain from certain
medications, such as bronchodilators, and foods before
performing a methacholine challenge test. The ATS
recommends whitholding caffeinated beverages the day of
the test (i.e. 8 h) prior to methacholine challenge.11 The
results of the MCT are expressed as the provocation
concentration causing a 20% FEV1 fall (PC20) which can be
used to determine the degree of AHR and bronchopro-
tection offered by medications or other substances.
eNO is used to assess eosinophilic airway inflammation.13
Asthmatics tend to have a predominant amount of type 2
helper cells which can be triggered by various stimuli which
ultimately leads to airway inflammation and an increased
level of eNO.14,15 This increase in eNO is thought to be due
to the high number of eosinophils and the expression of
inducible nitric oxide synthase (iNOS) in the airway smooth
muscle.16 Caffeine has been shown to decrease eNO17 but
not in asthmatic subjects.18
Additional investigations using current diagnostic tech-
niques (i.e. methacholine and eNO) should be studied
further and a larger sample size should be investigated. It is
hypothesized that the amount of caffeine in two cups of
coffee, approximately 330 mg, will not cause bronchodila-
tion or bronchoprotection significant enough to affect
methacholine PC20 results or influence levels of eNO.Methods
Subjects
Sixteen non smoking subjects with doctor-diagnosed mild to
moderate asthma were recruited, both known asthmatics
and volunteers. Amount of regular caffeine consumptionwas
not considered prior to enrolment but was examined post
hoc. Criteria for inclusion consisted of a diagnosis of current
asthma, a tidal breathing methacholine PC20 16mg/ml, anallergen exposure for4 weeks; subjects were requested to
refrain from caffeine-containing beverages for at least 8 h
prior to all testing. All subjects signed a consent form prior to
testing and the study was approved by the University of
Saskatchewan Biomedical Research Ethics Board.
Methacholine challenge test
The methacholine challenges were performed using the
standard 2 min tidal breathing challenge as outlined in the
current ATS guidelines.11 The tidal breathing method was
performed using a Bennett Twin jet nebulizer (Puritan
Bennett Corporation, Carlsbad, CA) calibrated to deliver an
output of 0.13 mg/ml. The subjects wore noseclips and the
aerosol was directed towards the mouth over a period of
2 min via a loose-fitting facemask. Complete baseline
spirometry was initially performed in triplicate and trun-
cated FEV1 manoeuvres were performed at 30 and 90 s after
the completion of each 2 min inhalation period. The next
cycle started 5 min after the start of the previous cycle.
Normal (0.9%) saline was inhaled first followed by doubling
doses of methacholine. Concentrations from 0.03 mg/mL to
256 mg/mL were available. The change in FEV1 was calcu-
lated from the lowest post-saline FEV1 and lowest post-
methacholine FEV1. The challenge continued until FEV1
fell 17%. PC20 was then interpolated or extrapolated from
the log dose vs. response curve algebraically.
Fraction exhaled nitric oxide and blood samples
eNO was measured using a chemiluminescence gas analyzer
(Niox, Aerocrine Inc., New York, NY). Subjects performed
an inhalation to total lung capacity followed by an exha-
lation with a constant flow rate of 50 ml/s via a mouth-
piece. Measurements were made in triplicate and recorded
in parts per billion (ppb).
Two blood samples were collected on separate days from
all consenting subjects 60 min post ingestion of caffeinated
or decaffeinated treatment to capture peak serum levels of
caffeine.15 The two blood samples were stored and sent to
Pharmalytics (Saskatoon, SK) for the determination of
serum caffeine levels.
Study design
A randomized single-blind crossover design was conducted
with 16 subjects undergoing twomethacholine challenges on
separate days, at least 24 h apart but nomore than oneweek
apart, at the same time of day. Subjects were blinded as to
which treatment they were receiving. One methacholine
challenge test was performed after drinking a caffeinated
(16oz) cup of coffee and the other was performed after
drinking a decaffeinated cup of coffee of the same size. The
caffeinated coffee had approximately 330 mg of caffeine,
and the decaffeinated coffee had approximately 25 mg of
caffeine. Subjects were randomly placed into caffeinated
and decaffeinated treatments on their first visit; every
second subject received caffeinated coffee as the first
intervention. On both days of testing, eNO and FEV1 were
measured prior to treatment. One hour post ingestion of
Table 1 Subject demographics including baseline FEV1 and FeNO values.
Subject # Gender Age Height
(in)
Weight
(lbs)
Baseline
FEV1 (Litres)
Predicted
FEV1 (%)
Baseline
FeNO (ppb)
Routinely
Ingest Caffeine
1 F 21 65 150 3.80 108 82 Y
2 M 21 69 165 4.67 103 23 N
3 F 20 64 145 3.25 94 16 Y
4 F 33 62 120 2.78 94 32 Y
5 F 45 66 150 2.80 93 10 Y
6 M 63 66 150 2.31 72 31 Y
7 F 22 61 129 2.99 95 56 N
8 F 20 65 190 3.00 84 16 N
9 M 24 66 145 2.77 67 47 N
10 F 26 64 145 3.28 99 16 Y
11 M 33 70 180 3.69 85 27 Y
12 M 20 75 170 4.96 95 41 Y
13 F 26 63 175 2.70 84 21 Y
14 F 21 66 125 3.52 98 19 Y
Mean Values 9F/5M 28 66 153 3.32 91 31 10Y/4N
1608 M.T. Yurach et al.either treatment, blood samples were collected and, eNO
and FEV1 measurements repeated. Once these two
measurements were collected the MCTwas done.
Statistical analysis
The study, with 14 subjects, had a 90% power to detect
a difference in log PC20 of 0.099; this represents approxi-
mately a one third doubling concentration difference which
is less than the minimum clinically significant difference of
a one half doubling concentration change. Differences in
mean FEV1 and eNO values between baseline and post
treatmentswere compared using the Student’s paired t-test.
Since histamine/methacholine PC20 values are log-normally
distributed,19 methacholine PC20 values were log trans-
formed prior to analysis. A p value <0.05 was considered
statistically significant. The correlation between broncho-
protection (caffeinatedminus decaf dose-shiftZD log PC20/
0.3) and serum caffeine level (caffeinated minus decaf) was
determined using linear regression analysis.
Results
Two of the 16 subjects were excluded because they did not
have a positive MCT. Fourteen subjects (5 males) were
included in the statistical analysis. The 14 subjectsTable 2 Caffeinated and decaffeinated treatments (n Z 14).
Caffeinated
Pre
FEV1 (L) 3.31  0.75
eNO (ppb) 31.2  19.6
Serum Caffeine (mg/mL)
log PC20
Geometric Mean PC20 (mg/mL)
eNO levels were higher at both times on the decaffeinated day (p <
aThere was a slight (5%) reduction in eNO after decaffeinated coffeecompleted the study without adverse event, the major
adverse event of concern being severe methacholine
induced bronchonstriction. Of the fourteen subjects,
twelve consented to providing blood samples. Subject
demographics including gender, baseline values and if they
routinely ingest caffeine, a post hoc item of interest, are
shown in Table 1. All subjects had a baseline % predicted
FEV1  65 and the majority of subjects regularly ingested
caffeine on a daily basis (71%).
There were no significant differences (p> 0.05) between
pre-caffeinated and post-caffeinated coffee in FEV1 or eNO
(Table 2). There was no effect of decaffeinated coffee on
FEV1, however there was a small (5%) reduction in eNO after
decaffeinated coffee (p < 0.05, Table 2). eNO levels were
also higher (p < 0.05) both before and after ingestion of
decaffeinated coffee when compared to the caffeinated day
(Table 2). There was no treatment sequence effect.
In Fig. 1 the individual and mean differences in meth-
acholine PC20 between the caffeinated and decaffeinated
treatments are shown. No significant difference (pZ 0.99)
in log methacholine PC20 values was seen. Geometric mean
PC20’s were 1.35 and 1.36 mg/mL for caffeinated and
decaffeinated coffee respectively.
The serum caffeine levels between the caffeinated and
decaffeinated treatments were 4.33  1.60 mg/mL and
1.39  1.18 mg/mL respectively. Serum caffeine levels
varied between each subject and caffeine was detected inDecaffeinated
Post Pre Post
3.36  0.74 3.31  0.69 3.31  0.76
31.5  20.4 35.7  23.5 33.6  22.2a
4.33  1.6 1.39  1.18
0.129  0.45 0.132  0.48
1.35 1.36
0.05).
(p < 0.05).
Figure 1 Methacholine PC20 (mg/mL) 1 h after 16 ounces of
caffeinated coffee (left) and 1 h after decaf coffee (right). The
solid circles are those (nZ 8) who received caffeinated coffee
first and the open circles those (n Z 6) who received decaf-
feinated coffee first; the 2 non evaluable subjects were from
this group.
Figure 2 Linear regression of the difference in caffeine
serum levels (mg/mL) on the vertical axis and methacholine
dose shift on the horizontal axis. The caffeine level difference
was calculated as active minus placebo. The dose shift is
defined as log PC20 after caffeine minus log PC20 after decaf
divided by 0.3 (ie the log of 2).
Coffee and methacholine responsiveness 1609the decaffeinated group, presumably due to the small
amount of caffeine in the decaffeinated coffee or to
residual levels from chronic consumption.
Linear regression of the differences in caffeine blood
levels against the methacholine PC20 dose shift is shown in
Fig. 2 (nZ 12). Ten subjects were within the 1 dose shift
in methacholine PC20. There was a moderate correlation
(r Z 0.69, p Z 0.013) seen with increasing caffeine level
difference and a positive dose shift. Two subjects are
outside of the 1 dose shift in methacholine PC20, one in
each direction, but within a 2 dose shift in methacholine
PC20.
Discussion
The results support the hypothesis that the ingestion of two
cups of caffeinated coffee does not change the outcomes of
FEV1, eNO or methacholine PC20 values when compared to
decaffeinated coffee. We found no significant difference in
the mean FEV1 values (i.e. no bronchodilation); no signifi-
cant difference in methacholine PC20 (i.e. no bronchopro-
tection) and no effect on eNO levels following caffeine
intake. Therefore individuals who regularly consume two
cups of coffee do not need to withhold ingestion prior to
pulmonary function testing.This study followed the ATS guidelines in avoiding
caffeine (except for the small amount in the decaffeinated
coffee) for 8 h.11 Measurements were made at 1 h which
approximates peak caffeine levels which are reported to
occur 30e120 min following consumption.20 The half life of
caffeine is quite variable but in the range of 3e6 h.20 Thus
the (minimum) 24 h washout in non-coffee drinkers would
be in the range of the 5 half lives which is considered an
adequate washout time. Since most subjects were tested in
the mornings and had avoided coffee for more than 12 h,
the washout in our coffee drinking subjects was likely in the
range of 3 half lives. The small level of serum caffeine in
the placebo period is, therefore, most likely due to the
residual amount of caffeine in the decaffeinated prepara-
tion. We do not believe this is a major weakness, as the
caffeine levels were much greater after active treatment.
Taylor et al.18 concluded that caffeinated beverages did
not alter eNO levels in asthmatics. These findings were
inconsistent with previous research that showed caffeine
decreased eNO levels.17 Our findings showed that eNO
values did not differ significantly after caffeine treatment.
We did not anticipate caffeine to have an anti-
inflammatory effect, and would not expect an anti-
inflammatory treatment to have an effect on eNO after
a single dose. The small 5% statistically significant decrease
in eNO levels following the decaffeinated treatment is
likely a chance occurrence of little clinical relevance given
that the magnitude of the decrease would not alter the
interpretation of the test.
It has been suggested that caffeine offers bronchopro-
tection to the histamine challenge test (HCT).5 By
comparison, we did not detect an inhibitory effect of
caffeine on MCT (Fig. 1). The difference between study
outcomes is important given that MCT has largely replaced
HCT in both clinical and research applications. If current
guidelines and recommendations for MCT are based solely
on literature investigating the effect of caffeine on HCT
additional research and an update may indeed be
1610 M.T. Yurach et al.necessary. Other possible factors that could account for the
differences between our results and those of previous
investigations include the dose of caffeine, sample size and
the timing of the methacholine challenge post caffeine
consumption. We looked at a dose that is considered
“normal dietary intake” in a larger sample size and per-
formed MCT at 60 min post caffeine ingestion whereas
others have used higher doses in fewer subjects and per-
formed bronchoprovocation testing at 2.5 and 4 h after
caffeine ingestion.
A recent meta-analysis of 7 studies concluded that
caffeine has a small (approximately 5%) bronchodilator
effect.21 Our study was not designed to address broncho-
dilation, and with baseline FEV1 at 91% predicted, this
would be a poor population in which to demonstrate
bronchodilation. These subjects are, however, typical of
those referred for diagnostic methacholine challenge
testing, ie subjects with symptoms and normal spirometry.
Although this study has offered novel insight on how MCT
is affected by the consumption of caffeine and how
research subjects or patients need to prepare for MCT,
future dose response investigations and, if warranted,
response kinetics (i.e. onset and threshold) may be
beneficial.
In conclusion, the amount of caffeine in a normal dietary
serving of coffee (2 cups or 16 ounces) does not alter eNO
values or cause significant bronchoprotection or broncho-
dilation. These results suggest the possibility that it may
not be necessary to avoid this amount of caffeine prior to
bronchoprovocation testing.Conflict of interest statement
The authors (MTY, BED, and DWC) declare that they have no
conflict of interest, financial or otherwise, related to this
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